Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.
Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
Rates of opioid prescription use is higher among patients with cancer compared with patients who have never had cancer, even after survivorship.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).
The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.
Doses May Be Adjusted for Treating NSCLC Patients
Biosimilars and originator trastuzumab neoadjuvant therapy had a comparable effect on pathologic complete response rates.
New safety issues are detected in almost one-third of drugs approved by the US FDA in the first 3 years after approval.
Temozolomide, an antimitotic chemotherapy used to treat brain cancer, demonstrated the potential to increase depression in a mouse model.
A new CSTD significantly reduced surface contamination during a simulated antineoplastic hazardous drug administration when compared to baseline.
Long-acting NK-1 receptor antagonist rolapitant demonstrates significant efficacy in managing CINV in patients receiving HEC or MEC for cancer.
New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.
A common beta blocker, carvedilol, is found to have preventive properties against the sun-induced cell damage that leads to skin cancer.
Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.
Leflunomide, an immunosuppressor FDA-approved for rheumatoid arthritis, is effective against breast cancer in mouse study.
Zoledronic acid and clodranate are the recommended bisphosphonates for the adjuvant treatment of postmenopausal patients with breast cancer.
A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.
Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.
I was surprised to see an order for arsenic recently. What is this being used for?
In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.
Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.
What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?
In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.
There is a lot of talk about biosimilar drugs. What makes a drug a biosimilar?
Patients with cancer incur significant out-of-pocket costs before their Medicare drug benefits activate, and due to those costs, many patients with CML delayed starting their treatment.
A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|